Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity. (Q54599332)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity. (English)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

author name string

HimaBindu Chunduri

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

Clyde Crumpacker

2

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

Prem L Sharma

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

language of work or name

0 references

publication date

2 April 2011

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

414

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

34-41

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

2 references

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro synthesis of long DNA products in reactions with HIV-RT and nucleocapsid protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

K65R and K65A substitutions in HIV-1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Recombination during reverse transcription: an evaluation of the role of the nucleocapsid protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Human immunodeficiency virus reverse transcriptase and protease sequence database

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2011.03.007

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2011.03.007

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21459401

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54599332&oldid=1606750430"